Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Corso

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Current Stem Cell Research & Therapy|January 29, 2008
The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation?Alessandro Corso, Marzia Varettoni
Mediterranean Journal of Hematology and Infectious Diseases|September 13, 2017
Non-Secretory Myeloma: Ready for a new Definition?Alessandro Corso, Silvia Mangiacavalli
Hematology (Amsterdam, Netherlands)|July 16, 2005
Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironmentAlessandro Corso, Eleonora Ferretti, Mario Lazzarino
Mediterranean Journal of Hematology and Infectious Diseases|May 16, 2025
An Update of the Appropriate Sequencing for Salvage Therapies in Multiple MyelomaGregorio Barilà, Francesca Rezzonico, Laura Pavan, et al.
Leukemia Research|August 14, 2009
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patientsAlessandro Corso, Silvia Mangiacavalli, Marzia Varettoni, et al.
Haematologica|March 1, 2002
Advantages of using thalidomide for the management of refractory myeloma patientsAlessandro Corso, Angela Lorenzi, Ester Orlandi, et al.
Hematology (Amsterdam, Netherlands)|December 16, 2014
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective studyAlbert Oriol, Pilar Giraldo, Ioannis Kotsianidis, et al.
American Journal of Hematology|December 11, 2012
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myelomaSilvia Mangiacavalli, Lara Pochintesta, Cristiana Pascutto, et al.
Leukemia & Lymphoma|January 21, 2016
Implemented myeloma management with whole-body low-dose CT scan: a real life experienceSilvia Mangiacavalli, Sara Pezzatti, Fausto Rossini, et al.
Cancer|April 19, 2007
Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 yearsAlessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Current Stem Cell Research & Therapy|January 29, 2008
The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation?Alessandro Corso, Marzia Varettoni
Mediterranean Journal of Hematology and Infectious Diseases|September 13, 2017
Non-Secretory Myeloma: Ready for a new Definition?Alessandro Corso, Silvia Mangiacavalli
Hematology (Amsterdam, Netherlands)|July 16, 2005
Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironmentAlessandro Corso, Eleonora Ferretti, Mario Lazzarino
Mediterranean Journal of Hematology and Infectious Diseases|May 16, 2025
An Update of the Appropriate Sequencing for Salvage Therapies in Multiple MyelomaGregorio Barilà, Francesca Rezzonico, Laura Pavan, et al.
Leukemia Research|August 14, 2009
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patientsAlessandro Corso, Silvia Mangiacavalli, Marzia Varettoni, et al.
Haematologica|March 1, 2002
Advantages of using thalidomide for the management of refractory myeloma patientsAlessandro Corso, Angela Lorenzi, Ester Orlandi, et al.
Hematology (Amsterdam, Netherlands)|December 16, 2014
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective studyAlbert Oriol, Pilar Giraldo, Ioannis Kotsianidis, et al.
American Journal of Hematology|December 11, 2012
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myelomaSilvia Mangiacavalli, Lara Pochintesta, Cristiana Pascutto, et al.
Leukemia & Lymphoma|January 21, 2016
Implemented myeloma management with whole-body low-dose CT scan: a real life experienceSilvia Mangiacavalli, Sara Pezzatti, Fausto Rossini, et al.
Cancer|April 19, 2007
Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 yearsAlessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, et al.
Pageof 6